ReviewRNA biology2025
Alternative cleavage and polyadenylation: key regulatory mechanisms in health and disease.
Review in RNA biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- OIP5-AS1 Sponges miR-223-3p to Upregulate FoxO3 and Ameliorate Temporomandibular Joint Osteoarthritis by Inhibiting Chondrocyte Apoptosis.Journal of cellular and molecular medicine · 2026Article
- The alternative polyadenylation factor CFIm25 orchestrates macrophage antibacterial activity againstInfection and immunity · 2026Article
- Escorting mRNAs - the multifunctional and divergent roles of cap-chaperones in post-transcriptional gene expression.Journal of cell science · 2026Review
- Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes.iMeta · 2026Review
- Global landscape of alternative polyadenylation during the growth and development of skeletal muscle in pigs.BMC genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative polyadenylation (APA) is a critical post-transcriptional regulatory mechanism that generates diverse mRNA isoforms by selecting different polyadenylation sites within pre-mRNAs, thereby modulating the length of the 3' untranslated region (3' UTR), thereby fine-tuning gene expression and protein synthesis. APA regulation involves conserved cis-acting elements, trans-acting factors, and key protein complexes such as CPSF and CSTF, influenced by the cellular context and various RNA-binding proteins. To address the complexity of APA, comprehensive methodologies and computational tools have been developed, leading to extensive APA databases with detailed biological annotations. Recent advancements in high-throughput sequencing and single-cell technologies have enhanced our understanding of APA's dynamic regulation across tissues and developmental stages, revealing its significant impact on cellular heterogeneity and disease progression. APA plays essential roles in numerous physiological processes, including neuronal homoeostasis, immune regulation, cardiovascular and vascular development, myogenesis, and metabolism. Dysregulation of APA is associated with a wide range of diseases, including neurodegenerative disorders, autoimmune conditions, cardiovascular diseases, metabolic syndromes, and genetic disorders. Clinically, targeting APA regulatory mechanisms offers promising opportunities for therapeutic interventions and the development of personalized medical strategies. This review highlights the pivotal role of APA in gene regulation and disease, emphasizing the need for continued research to unravel its complex mechanisms and leverage its potential in advancing precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.